- In May 2024, Intuitive Surgical, Inc. announced expanded capabilities for its da Vinci Xi surgical system, optimizing it further for complex gynecologic procedures, including myomectomy. This upgrade aims to improve precision and flexibility during minimally invasive fibroid removal, reinforcing Intuitive Surgical’s leadership in robotic-assisted surgery and its role in advancing women's health solutions globally
- In March 2024, Olympus Corporation introduced its next-generation laparoscopic instruments tailored for gynecological surgeries, including myomectomy. These tools feature enhanced ergonomics and visualization support, offering surgeons better control and reducing operative time. The development aligns with Olympus’s strategy to drive innovation in minimally invasive gynecologic procedures
- In February 2024, Hologic, Inc. launched a global awareness campaign to educate women on uterine fibroid management and highlight myomectomy as a uterus-preserving treatment option. This initiative, supported by healthcare partners, aims to empower women to seek timely and informed care, promoting early diagnosis and increased adoption of surgical interventions
- In January 2024, Stryker Corporation announced the integration of artificial intelligence (AI)-powered analytics into its laparoscopic systems, enabling enhanced intraoperative decision-making during procedures such as myomectomy. The move reflects a growing trend of integrating digital tools to improve surgical outcomes and reduce complication rates in gynecological surgeries
- In December 2023, Medtronic plc expanded its gynecologic surgical device portfolio with the launch of a new bipolar energy device specifically designed for myomectomy. This innovation enhances tissue sealing and reduces blood loss during fibroid removal. Medtronic’s focus on developing precision tools for complex gynecological procedures supports the growing demand for minimally invasive uterine-sparing treatments worldwide
